Go offline with the Player FM app!
Episode 292 - Richard Pietroski
Manage episode 244775429 series 1547852
Richard Pietroski is President of Lung Bioengineering at United Therapeutics Corporation. Richard discusses the advancements his organization has made in ex-vivo lung perfusion (EVLP). His team’s revolutionary work has kept lungs outside the body for up to 22 hours, whereas in the past, lungs needed to be transplanted within six hours. Lung Bioengineering’s goal is to double the number of lungs transplanted annually in the U.S.
Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #ClinicalTrials @antidote_me
470 episodes
Manage episode 244775429 series 1547852
Richard Pietroski is President of Lung Bioengineering at United Therapeutics Corporation. Richard discusses the advancements his organization has made in ex-vivo lung perfusion (EVLP). His team’s revolutionary work has kept lungs outside the body for up to 22 hours, whereas in the past, lungs needed to be transplanted within six hours. Lung Bioengineering’s goal is to double the number of lungs transplanted annually in the U.S.
Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #ClinicalTrials @antidote_me
470 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.